首页> 外文期刊>Medicine. >Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis
【24h】

Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis

机译:Danggui-Shaoyao-san for Dementia:符合Prisma的系统评价和Meta分析

获取原文
获取外文期刊封面目录资料

摘要

Background: Although memory loss and other symptoms of dementia pose tremendous burdens on patients and societies, there is currently no cure for dementia . Methods: We conducted a systematic review and meta-analysis of the anti- dementia effects of Danggui-Shaoyao-San (DSS), which is derived from natural resources. We searched for randomized controlled trials (RCTs) from inception to June 2019. We searched PubMed, Embase, Korean databases (Research Information Service System and Oriental Medicine Advanced Searching Integrated System), Chinese databases (China Knowledge Resource Integrated Database and Wanfang Database), and Japanese databases (CiNii and J-STAGE). Studies were included if they were a RCT, investigated the efficacy of DSS or its modified form, and included participants with dementia . Use of DSS with other treatment (eg, acupuncture, anti- dementia drugs, etc) was included. Items of each trial were evaluated by 2 independent reviewers. Data were pooled by using random-effect models. Results: A total of 482 studies were identified, and 5 eligible studies for Alzheimer disease (AD) and 4 studies for vascular dementia (VD) were included in the final analysis, representing a total of 567 participants. As for AD, pooled results of the Mini-Mental State Examination (MMSE) (mean differences [MD] 4.60; 95% confidence interval [CI] 4.29, 4.91) and activities of daily living (MD 11.40; 95% CI 10.94, 11.86) favored DSS. DSS had synergistic effect with acupuncture over acupuncture alone in MMSE (MD 1.69; 95% CI 1.05, 2.34), Hasegawa Dementia Scale (MD.62; 95% CI –0.20, 1.44), and activities of daily living (MD 2.38; 95% CI 1.92, 2.85). In VD, pooled results showed a significant difference in the score of dementia scales such as MMSE and Hasegawa Dementia Scale compared with nootropic drugs. DSS significantly reduced symptoms (odds ratio 5.02, 95%, CI 2.76–9.11) in patients with VD. The respective size of each RCTs was small and some included studies were of low quality due to their limited description on methodological issues. Conclusion: These estimates suggest that DSS provides clinically important reductions in symptoms of AD and VD and can be a promising anti- dementia drug candidate.
机译:背景:虽然痴呆症的记忆丧失和其他症状对患者和社会的巨大负担,但目前没有治愈痴呆症。方法:我们对DangGui-Shaoyao-San(DSS)的抗抑郁症效应进行了系统审查和荟萃分析,这是来自自然资源的抗抑郁症效应。我们搜索了从2009年6月开始的随机对照试验(RCT)。我们搜索了PubMed,Embase,韩国数据库(研究信息服务系统和东方医学进程搜索综合系统),中国数据库(中国知识资源集成了数据库和Wanfang数据库),和日本数据库(CINII和J-阶段)。如果它们是RCT,则包括研究,研究了DSS或其修饰形式的疗效,并包括参与者的痴呆。包括DSS与其他治疗(例如,针灸,抗痴呆药物等)。每次试验的项目由2名独立审稿人评估。通过使用随机效果模型来汇集数据。结果:鉴定了482项研究,并列入了5种阿尔茨海默病(AD)和4种血管痴呆(VD)研究的符合条件的研究,该研究总计567名参与者。至于广告,戏剧态度检查的合并结果(MMSE)(平均差异[MD] 4.60; 95%置信区间[CI] 4.29,4.91)和日常生活活动(MD 11.40; 95%CI 10.94,11.86 )喜欢DSS。 DSS在MMSE(MD 1.69; 95%CI 1.05,2.34),Hasegawa痴呆尺度(MD.62; 95%CI -0.20,1.44)和日常生活活动(MD 2.38; 95 %CI 1.92,2.85)。在VD中,汇总结果显示出与垂直药物相比,如MMSE和Hapegawa痴呆率等痴呆率的得分显着差异。 VD患者中DSS显着降低症状(差距5.02,95%,CI 2.76-9.11)。每个RCT的各个规模很小,一些包括的研究具有低质量,因为它们的方法问题有限。结论:这些估计表明,DSS在广告和VD的症状方面提供临床重要的减少,并且可以成为一个有前途的抗抑郁症毒品候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号